Invitrogen™ Abciximab Recombinant Human Monoclonal Antibody (7E3 (Abciximab))

Description

Specificity: Recognises human CD41.

Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (alpha-v-beta-3) receptor found on platelets and vessel wall endothelial and smooth muscle cells. Abciximab binds to the intact platelet GpiIb/IIIa receptor, which is a member of the integrin family of adhesion receptors and the major platelet surface receptor involved in platelet aggregation. This binding is thought to involve steric hindrance and/or conformational alterations which block access of large molecules to the receptor rather than direct interaction with the RGD (arginine-glycine-aspartic acid) binding site of GpiIb/IIIa. By binding to the vitronectin receptor (also known as the alpha-v-beta-3 integrin), abciximab blocks effects mediated by this integrin which include cell adhesion. Furthermore, abciximab blocks Mac-1 receptor on monocytes and neutrophils thus inhibiting monocyte adhesion.